VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ONCY
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ONCYOncolytics Biotech Inc.
$0.44$56M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksONCYBalance Sheet

Oncolytics Biotech Inc. (ONCY) Balance Sheet

27Y historyFree accessUpdated daily

The financial position has weakened significantly, with total liabilities of $13.3 million now exceeding total assets of $8.2 million, resulting in a negative equity balance of -$5.1 million as of 2026Q1.

Income StatementBalance SheetCash FlowRatios

ONCY Balance Sheet

Annual statement

ONCY Balance Sheet

Oncolytics Biotech Inc. (ONCY) balance sheet — 27-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99
Total Current Assets5.27M9.39M18.88M38.17M35.68M44.9M33.74M18.93M14.45M17.82M14.44M26.92M16.67M27.69M21.67M35.63M43.47M36.34M13.54M25.55M28.34M40.99M34.22M20.97M8.44M15.09M17.8M4.58M
Cash & Short-Term Investments2.43M7.14M15.94M34.91M32.14M41.26M31.22M14.15M13.7M11.84M14.12M26.08M16.18M27.22M21.29M34.86M42.91M35.74M13.28M25.21M27.61M40.41M33.92M20.75M8.32M14.97M17.62M4.55M
Cash Only2.43M7.14M15.94M34.91M11.67M41.26M31.22M14.15M13.7M11.84M12.03M24.02M14.15M25.22M19.32M32.92M39.3M33.98M7.43M6.72M3.49M3.51M12.41M2.64M8.32M14.97M17.62M4.55M
Short-Term Investments000020.47M000002.09M2.06M2.03M2M1.97M1.94M3.61M1.76M5.85M18.5M24.12M36.89M21.51M18.11M0000
Accounts Receivable1.2M786.23K68K15K521K866K0051.65K4.8M54.41K340.06K0044.98K55.39K284.99K64.79K86.32K80.08K84K47.39K47.77K048.54K95.32K137.72K19.75K
Days Sales Outstanding--------------3.38------22.0824.92-84.82-162.15-
Inventory0000000000000000023.9K000540.37K250.36K156.84K024.19K00
Days Inventory Outstanding-----------------2.31----------
Other Current Assets00980K00089.66K2.07M00000000000000000-239.34K15.29K
Total Non-Current Assets558K1.01M1.31M647K1.65M976K609.13K727.48K412.74K333.44K319.95K459.82K525.38K532.46K409.25K392.11K962.59K934.35K444.68K5.23M5.23M5.3M5.27M5.08M9.52M3.98M3.86M2.58M
Property, Plant & Equipment558K1.01M1.31M647K652K976K609.13K727.48K412.74K333.44K319.95K459.82K525.38K532.46K409.25K392.11K226.91K218.13K263.93K201.1K149.6K189.86K5.26M290.5K308.94K211.12K58.9K18.29K
Fixed Asset Turnover0.00x-------------11.85x------4.13x0.13x1.08x0.68x-5.26x-
Goodwill0000000000000000000000000000
Intangible Assets000000000000000000180.75K5.03M0004.67M4.21M3.77M3.8M2.56M
Long-Term Investments00000000000000000716.22K0000000000
Other Non-Current Assets0000998K00000000000735.68K0005.08M5.11M12K111.42K5.01M000
Total Assets5.83M10.4M20.19M38.82M37.33M45.88M34.35M19.66M14.87M18.15M14.76M27.38M17.19M28.22M22.08M36.02M44.43M37.27M13.99M30.78M33.57M46.29M39.49M26.05M17.97M19.07M21.66M7.16M
Asset Turnover0.00x-------------0.22x------0.02x0.02x0.01x0.01x-0.01x-
Asset Growth %-243.88%-48.46%-48%3.98%-18.63%33.58%74.72%32.24%-18.1%22.98%-46.11%59.27%-39.08%27.83%-38.71%-18.92%19.22%166.46%-54.56%-8.29%-27.5%17.23%51.58%44.98%-5.79%-11.94%202.33%-
Total Current Liabilities5.92M8.37M6.69M4.24M3.94M2.69M2.71M12.87M2.81M5.23M4.07M2.71M3.37M6.01M7.29M6.5M2.5M4.43M4.53M2.82M2.62M1.69M949.26K884.93K1.26M2.32M604.89K86.1K
Accounts Payable3.21M4.81M1.09M1.08M2.25M594K1.81M3.17M1.83M3.51M4.07M2.71M3.37M6.01M7.29M00002.82M2.62M1.69M949.26K884.93K1.26M2.32M604.89K86.1K
Days Payables Outstanding68.72K-------6.99K14.1K9.15K5.48K--548.55-------------
Short-Term Debt133K000000000000000000000000000
Deferred Revenue (Current)00000000927.4K1.55M000000000000000000
Other Current Liabilities2.57M3.3M1.62M532K79K408K655.21K9.36M61.32K0000006.5M2.5M4.43M4.53M000000000
Current Ratio0.89x1.12x2.82x9.01x9.05x16.69x12.45x1.47x5.13x3.41x3.55x9.94x4.94x4.61x2.97x5.48x17.38x8.21x2.99x9.06x10.83x24.22x36.05x23.70x6.70x6.50x29.42x53.24x
Quick Ratio0.89x1.12x2.82x9.01x9.05x16.69x12.45x1.47x5.13x3.41x3.55x9.94x4.94x4.61x2.97x5.48x17.38x8.20x2.99x9.06x10.83x23.90x35.78x23.52x6.70x6.49x29.42x53.24x
Cash Conversion Cycle----------------------------
Total Non-Current Liabilities7.42M7.24M7.52M7.02M6.89M7.09M6.88M6.9M5.86M4.64M0000000001150K150K150K150K150K797.62K1.14M150K
Long-Term Debt00000000000000000000150K150K150K150K150K150K150K150K
Capital Lease Obligations1.3M507.69K787K290K157K361K153.17K166.43K00000000000000000000
Deferred Tax Liabilities0000000000000000000000000647.62K988.19K0
Other Non-Current Liabilities2.23M000006.73M6.73M52.43K0000000000100000000
Total Liabilities13.34M15.62M14.2M11.26M10.83M9.78M9.59M19.77M8.67M9.87M4.07M2.71M3.37M6.01M7.29M6.5M2.5M4.43M4.53M2.82M2.77M1.84M1.1M1.03M1.41M3.12M1.74M236.1K
Total Debt410K772.51K1.06M423K373K655K402.06K506.27K000000000000150K150K150K150K150K150K150K150K
Net Debt-2.02M-6.37M-14.88M-34.49M-11.29M-40.61M-30.82M-13.64M-13.7M-11.84M-12.03M-24.02M-14.15M-25.22M-19.32M-32.92M-39.3M-33.98M-7.43M-6.72M-3.34M-3.36M-12.26M-2.49M-8.17M-14.82M-17.47M-4.4M
Debt / Equity-0.05x-0.18x0.02x0.01x0.02x0.02x-------------0.00x0.00x0.00x0.01x0.01x0.01x0.01x0.02x
Debt / EBITDA-0.01x---------------------------
Net Debt / EBITDA0.05x---------------------------
Interest Coverage----------------------------
Total Equity-7.5M-5.21M5.98M27.56M26.5M36.1M24.75M-107.89K6.2M8.28M10.69M24.67M13.82M22.21M14.79M29.52M41.93M32.84M9.45M27.96M30.8M44.45M38.39M25.02M16.56M15.95M19.92M6.93M
Equity Growth %-7168.12%-187.13%-78.29%4%-26.59%45.84%23041.96%-101.74%-25.21%-22.51%-56.68%78.55%-37.79%50.22%-49.91%-29.6%27.67%247.44%-66.19%-9.22%-30.71%15.79%53.46%51.08%3.79%-19.89%187.47%-
Book Value per Share-0.06-0.050.080.410.460.670.61-0.000.390.590.852.081.492.531.853.956.386.322.176.578.0612.9112.7710.197.448.2010.890.11
Total Shareholders' Equity-7.5M-5.21M5.98M27.56M26.5M36.1M24.75M-107.89K6.2M8.28M10.69M24.67M13.82M22.21M14.79M29.52M41.93M32.84M9.45M27.96M30.8M44.45M38.39M25.02M16.56M15.95M19.92M6.93M
Common Stock00438.19M430.91M404.04M391.35M356.82M311.08M285.19M271.71M262.32M261.32M237.66M228.61M198.16M177.28M0138.12M0000000000
Retained Earnings-457.88M-589.32M-477.71M-446M-418.25M-393.42M-367.11M-344.61M-311.48M-294.45M-278.83M-263.69M-249.97M-231.35M-207.81M-171.44M-138.76M-124.38M-102.56M-80.52M-65.03M-50.73M-37.95M-24.99M-16.45M-10.36M-4.19M-574.46K
Treasury Stock0000000000000000000000000000
Accumulated OCI6.22M8.54M961K544K662K388K4.02M4.08M4.23M373.73K554.06K760.98K280.04K79.7K-57.12K-117.5K-513.84K-450.77K-385.84K5.35M4.22M4.43M9.7M5.3M2.7M2.5M2.5M2.5M
Minority Interest0000000000000000000000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Imminent liquidity depletion risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Rapid Erosion of Financial Position

As reported in recent financial statements, ONCY's total assets have plummeted from $38.8 million in 2023Q4 to just $8.2 million by 2026Q1, reflecting a consistent and aggressive depletion of capital reserves as the company continues its pre-revenue clinical development phase without any offsetting commercial inflows.

The consistent decline in total assets over the last ten quarters suggests that the company is consuming its primary resource base to fund ongoing R&D activities. This trajectory indicates that the business model remains entirely dependent on external capital markets, as the balance sheet shows no signs of stabilization or organic growth.

Critical Contraction of Cash Runway

Based on the provided quarterly data, the company's cash position has deteriorated significantly, falling from $34.9 million in 2023Q4 to $5.5 million in 2026Q1, which leaves the firm with a dangerously thin buffer against its ongoing operational burn and clinical trial obligations.

The current ratio has compressed from a high of 9.01 in 2023Q4 to 1.38 in 2026Q1, signaling a substantial reduction in the company's ability to cover short-term liabilities. Investors should monitor this trend closely, as the current liquidity profile appears insufficient to support long-term clinical trial milestones without immediate financing.

Negative Equity and Dilution Pressure

According to the latest balance sheet figures, ONCY's equity has shifted into negative territory, reaching -$5.1 million in 2026Q1, a stark reversal from the $27.6 million reported in 2023Q4 that highlights the cumulative impact of persistent net losses and aggressive capital consumption.

The transition to negative equity suggests that the company has exhausted its initial capital base, forcing a reliance on dilutive financing to maintain operations. This structural weakness may limit future strategic flexibility and suggests that existing shareholders face continued risk of dilution as the company seeks to recapitalize.

Hidden Risks in Liability Structure

As indicated by the most recent filings, the company's total liabilities of $13.3 million in 2026Q1 now exceed total assets, creating a balance sheet imbalance that warrants further investigation into the nature of these obligations and their potential impact on future solvency.

The presence of significant accrued liabilities alongside a shrinking asset base implies that the company is operating with limited margin for error. This configuration suggests that any delay in clinical trial progress or failure to secure new funding could lead to immediate solvency challenges, as there are few tangible assets to leverage.

ONCY — Frequently Asked Questions

Quick answers to the most common questions about buying ONCY stock.

What are the total assets of Oncolytics Biotech Inc. (ONCY)?

As of 2025, Oncolytics Biotech Inc. (ONCY) had total assets of $10.4M including $9.4M in current assets.

How much debt does Oncolytics Biotech Inc. (ONCY) have?

Oncolytics Biotech Inc. (ONCY) carries total debt of $0.8M, offset by $7.1M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Oncolytics Biotech Inc.?

Oncolytics Biotech Inc. (ONCY) has total shareholders' equity (book value) of $-5.2M ($-0.05 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Oncolytics Biotech Inc.'s current ratio and liquidity?

Oncolytics Biotech Inc. (ONCY) reported a current ratio of 1.12x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.